Innovex International vs NOV
INVX and NOV side by side, both in construction, mining, and materials handling. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INVX and NOV compare
NOV is the larger company, worth 3.6 times as much as Innovex International ($6.0B against $1.7B).
On earnings, Innovex International is cheaper: it trades at 26.6× trailing earnings, against 42.3× for NOV.
Innovex International grew revenue faster over the last twelve months (15.0% versus −0.98% for NOV).
Innovex International keeps more of each dollar of sales as profit, with a net margin of 6.2% compared with 1.6% at NOV.
NOV pays a dividend yielding 2.6%; Innovex International does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INVX | NOV |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $6.0B |
| Share price | $23.68 | $16.92 |
| Change, 1 year | 7.2% | 7.6% |
| Change, 5 years | 22.4% | 35.5% |
| Beta (5Y) | 0.28 | 0.18 |
| Employees | 2,160 | 35K |
| StockData Score | ||
| Total score | 10 | 10 |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 26.6× (better) | 42.3× |
| P/S | 1.7× | 0.7× (better) |
| P/B | 1.6× | 1.0× (better) |
| EV/EBITDA | 8.9× | 8.0× (better) |
| P/FCF | – | 22.3× |
| FCF yield | – | 4.5% |
| Fair value | $22.82 | $15.81 |
| Margin of safety | −3.8% (better) | −7.0% |
| Growth | ||
| Revenue growth (TTM) | 15.0% (better) | −0.98% |
| Revenue growth, 5Y average | 21.8% (better) | 7.5% |
| Net income growth (TTM) | −57.4% (better) | −62.7% |
| EPS growth (TTM) | −67.6% | −60.0% (better) |
| Profitability | ||
| Gross margin | 32.4% (better) | 20.7% |
| Operating margin | 10.0% (better) | 5.5% |
| Net margin | 6.2% (better) | 1.6% |
| FCF margin | – | 3.1% |
| Return on equity | 6.0% (better) | 2.3% |
| Return on invested capital | 6.8% (better) | 3.4% |
| Financial health | ||
| Debt / equity | 0.02 (better) | 0.27 |
| Net debt / EBITDA | −1.21 | 0.77 (better) |
| Interest coverage | 345× (better) | 5.5× |
| Current ratio | 5.01 (better) | 2.51 |
| Altman Z-score | 5.56 (better) | 1.95 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.6% |
| Payout ratio | – | 109% |
| Years of dividend growth | – | 2 |
| Dividend growth, 5Y average | – | 59.1% |
| Buyback yield | 0.85% | 3.8% (better) |
| Shareholder yield | 0.85% | 6.4% (better) |
| Ownership | ||
| Held by institutions | 73.5% | 109% |
| Held by insiders | – | 1.2% |
| Insider net buying, 12 months | −$615M | −$4.6M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 7.8% |
Go deeper
- INVX stock overview
- INVX income statement
- INVX valuation and score
- NOV stock overview
- NOV income statement
- NOV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.